RxDoctor Payments Data

Tanya Khan

Gastroenterology · Concord, MANPI 1427582741

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,313 and has fallen 82.3% since, to $232 in 2025.

$2,008in general payments, 2019–2025

Across 61 payments — averaging $32.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$425
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$394
  • Johnson & Johnson$276
  • Takeda Pharmaceuticals U.S.A., Inc.$267
  • Phathom Pharmaceuticals, Inc.$136
  • E.r. Squibb & Sons, L.L.C.$134
  • plus $376 from 5 others

What the payments were for

  • Food & beverage$2,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,008 in reported general payments places this provider in the 60th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$74,624
Medicare patients
259
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin12$27,199
LinzessLinaclotide20$13,072
SutabSod Sulf/Pot Chloride/Mag Sulf29$4,716
Omeprazole77$1,291
Pantoprazole Sodium34$440
Famotidine15$137
Prednisone11$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$394$27,19912 claims
AbbVieLinzess$425$13,07220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Concord

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →